Vect-Horus S.A.S.

Vect-Horus S. A. S. is a biotechnology company specializing in advanced drug delivery systems that enhance therapeutic efficacy, particularly across the blood-brain barrier, targeting neurological disorders.

Founded in 2005 in Marseille, France, Vect-Horus focuses on innovative drug delivery solutions. The company has successfully completed 12 deals, with its most recent funding round occurring on February 20, 2023, raising EUR 4. 04 mn from investors including Alpha Centauri and CAAP Creation. The company's total amount raised to date is EUR 4.

04 mn, with a current valuation of EUR 57. 097 mn. Vect-Horus specializes in advanced drug delivery systems, focusing on technology that facilitates the passage of therapeutic agents across the blood-brain barrier. Their proprietary platforms enhance the efficacy of central nervous system therapies and address challenges related to neurological disorders.

The company serves pharmaceutical companies, research institutions, and healthcare providers across Europe and North America, emphasizing mRNA-based therapeutics and partnerships in the biotechnology sector. The company's revenue is generated through strategic partnerships, collaborations with pharmaceutical firms, and possible licensing agreements, ensuring access to its proprietary technologies. Vect-Horus plans to leverage the EUR 4. 04 mn raised in February 2023 to advance its drug delivery systems and expand its market presence.

The company seeks to launch new products aimed at enhancing the treatment of central nervous system disorders and is targeting growth in additional regions beyond its current markets in Europe and North America.